EXCLUSIVITY SUMMARY

NDA # 205395          SUPPL #          HFD # 530 (DAVP)

Trade Name:  PREZCOBIX

Generic Name:  darunavir and cobicistat

Applicant Name:  Janssen Products, LP

Approval Date, If Known:  January 29, 2015

PART I  IS AN EXCLUSIVITY DETERMINATION NEEDED?

1.  An exclusivity determination will be made for all original applications, and all efficacy supplements. Complete PARTS II and III of this Exclusivity Summary only if you answer "yes" to one or more of the following questions about the submission.

   a)  Is it a 505(b)(1), 505(b)(2) or efficacy supplement?  

      YES ☒  NO ☐

   If yes, what type? Specify 505(b)(1), 505(b)(2), SE1, SE2, SE3, SE4, SE5, SE6, SE7, SE8

   505(b)(1)

   c)  Did it require the review of clinical data other than to support a safety claim or change in labeling related to safety?  (If it required review only of bioavailability or bioequivalence data, answer "no.")

      YES ☐  NO ☒

   If your answer is "no" because you believe the study is a bioavailability study and, therefore, not eligible for exclusivity, EXPLAIN why it is a bioavailability study, including your reasons for disagreeing with any arguments made by the applicant that the study was not simply a bioavailability study.

The sponsor submitted BA and BE study data in healthy volunteers, and data from a single-arm, open label study in patients with HIV-1 infection. The BA study, TMC114IFD1001, evaluated two different formulations of darunavir/cobicistat FDC formulations compared to darunavir co-administered with ritonavir. The BE study, TMC114FD1003, evaluated the BE of the darunavir/cobicistat FDC tablet compared to the individual cobicistat and darunavir tablets. The BE data was considered pivotal and required for approval.  The open label study, GS-US-216-0130, evaluating the safety and efficacy of the darunavir/cobicistat FDC was reviewed to support the safety of the product, but was not needed for approval.
If it is a supplement requiring the review of clinical data but it is not an effectiveness supplement, describe the change or claim that is supported by the clinical data:

d) Did the applicant request exclusivity?  
   YES ☒   NO ☐

If the answer to (d) is "yes," how many years of exclusivity did the applicant request?

   3 years

e) Has pediatric exclusivity been granted for this Active Moiety?  
   YES ☐   NO ☒

If the answer to the above question in YES, is this approval a result of the studies submitted in response to the Pediatric Written Request?

IF YOU HAVE ANSWERED "NO" TO ALL OF THE ABOVE QUESTIONS, GO DIRECTLY TO THE SIGNATURE BLOCKS AT THE END OF THIS DOCUMENT.

2. Is this drug product or indication a DESI upgrade?  
   YES ☐   NO ☒

IF THE ANSWER TO QUESTION 2 IS "YES," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8 (even if a study was required for the upgrade).

PART II      FIVE-YEAR EXCLUSIVITY FOR NEW CHEMICAL ENTITIES
(Answer either #1 or #2 as appropriate)

1. Single active ingredient product.

Has FDA previously approved under section 505 of the Act any drug product containing the same active moiety as the drug under consideration? Answer "yes" if the active moiety (including other esterified forms, salts, complexes, chelates or clathrates) has been previously approved, but this particular form of the active moiety, e.g., this particular ester or salt (including salts with hydrogen or coordination bonding) or other non-covalent derivative (such as a complex, chelate, or clathrate) has not been approved. Answer "no" if the compound requires metabolic conversion (other than deesterification of an esterified form of the drug) to produce an already approved active moiety.

   YES ☐   NO ☒
If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA #(#s).

NDA#
NDA#
NDA#

2. Combination product.

If the product contains more than one active moiety (as defined in Part II, #1), has FDA previously approved an application under section 505 containing any one of the active moieties in the drug product? If, for example, the combination contains one never-before-approved active moiety and one previously approved active moiety, answer "yes." (An active moiety that is marketed under an OTC monograph, but that was never approved under an NDA, is considered not previously approved.)

YES ☑️    NO ☐

If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA #(#s).

NDA#  21976  Prezista (darunavir), Tablet, Film-coated
NDA#  202895 Prezista (darunavir), Suspension
NDA#  203100  Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), Tablet
NDA#  203094  Tybost (cobicistat), Tablet

IF THE ANSWER TO QUESTION 1 OR 2 UNDER PART II IS "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8. (Caution: The questions in part II of the summary should only be answered "NO" for original approvals of new molecular entities.) IF “YES,” GO TO PART III.

PART III    THREE-YEAR EXCLUSIVITY FOR NDAs AND SUPPLEMENTS

To qualify for three years of exclusivity, an application or supplement must contain "reports of new clinical investigations (other than bioavailability studies) essential to the approval of the application and conducted or sponsored by the applicant." This section should be completed only if the answer to PART II, Question 1 or 2 was "yes."
1. Does the application contain reports of clinical investigations? (The Agency interprets "clinical investigations" to mean investigations conducted on humans other than bioavailability studies.) If the application contains clinical investigations only by virtue of a right of reference to clinical investigations in another application, answer "yes," then skip to question 3(a). If the answer to 3(a) is "yes" for any investigation referred to in another application, do not complete remainder of summary for that investigation.

YES ☒ NO ☐

IF "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8.

2. A clinical investigation is "essential to the approval" if the Agency could not have approved the application or supplement without relying on that investigation. Thus, the investigation is not essential to the approval if 1) no clinical investigation is necessary to support the supplement or application in light of previously approved applications (i.e., information other than clinical trials, such as bioavailability data, would be sufficient to provide a basis for approval as an ANDA or 505(b)(2) application because of what is already known about a previously approved product), or 2) there are published reports of studies (other than those conducted or sponsored by the applicant) or other publicly available data that independently would have been sufficient to support approval of the application, without reference to the clinical investigation submitted in the application.

(a) In light of previously approved applications, is a clinical investigation (either conducted by the applicant or available from some other source, including the published literature) necessary to support approval of the application or supplement?

YES ☐ NO ☒

If "no," state the basis for your conclusion that a clinical trial is not necessary for approval AND GO DIRECTLY TO SIGNATURE BLOCK ON PAGE 8:

Cobicistat co-administered with darunavir was approved in September 2014. The only data essential to the approval of the fixed-dose formulation of darunavir and cobicistat is the bioequivalence study, TMC1141FD1003.

(b) Did the applicant submit a list of published studies relevant to the safety and effectiveness of this drug product and a statement that the publicly available data would not independently support approval of the application?

YES ☐ NO ☒

(1) If the answer to 2(b) is "yes," do you personally know of any reason to disagree with the applicant's conclusion? If not applicable, answer NO.

YES ☐ NO ☒

If yes, explain:
(2) If the answer to 2(b) is "no," are you aware of published studies not conducted or sponsored by the applicant or other publicly available data that could independently demonstrate the safety and effectiveness of this drug product?

YES ☐ NO ☐

If yes, explain:

(c) If the answers to (b)(1) and (b)(2) were both "no," identify the clinical investigations submitted in the application that are essential to the approval:

Studies comparing two products with the same ingredient(s) are considered to be bioavailability studies for the purpose of this section.

3. In addition to being essential, investigations must be "new" to support exclusivity. The agency interprets "new clinical investigation" to mean an investigation that 1) has not been relied on by the agency to demonstrate the effectiveness of a previously approved drug for any indication and 2) does not duplicate the results of another investigation that was relied on by the agency to demonstrate the effectiveness of a previously approved drug product, i.e., does not redemonstrate something the agency considers to have been demonstrated in an already approved application.

a) For each investigation identified as "essential to the approval," has the investigation been relied on by the agency to demonstrate the effectiveness of a previously approved drug product? (If the investigation was relied on only to support the safety of a previously approved drug, answer "no.")

Investigation #1 YES ☐ NO ☐
Investigation #2 YES ☐ NO ☐

If you have answered "yes" for one or more investigations, identify each such investigation and the NDA in which each was relied upon:

b) For each investigation identified as "essential to the approval", does the investigation duplicate the results of another investigation that was relied on by the agency to support the effectiveness of a previously approved drug product?
Investigation #1  

Investigation #2

If you have answered "yes" for one or more investigation, identify the NDA in which a similar investigation was relied on:

c) If the answers to 3(a) and 3(b) are no, identify each "new" investigation in the application or supplement that is essential to the approval (i.e., the investigations listed in #2(c), less any that are not "new"):

4. To be eligible for exclusivity, a new investigation that is essential to approval must also have been conducted or sponsored by the applicant. An investigation was "conducted or sponsored by" the applicant if, before or during the conduct of the investigation, 1) the applicant was the sponsor of the IND named in the form FDA 1571 filed with the Agency, or 2) the applicant (or its predecessor in interest) provided substantial support for the study. Ordinarily, substantial support will mean providing 50 percent or more of the cost of the study.

a) For each investigation identified in response to question 3(c): if the investigation was carried out under an IND, was the applicant identified on the FDA 1571 as the sponsor?

Investigation #1

Investigation #2

IND #

(b) For each investigation not carried out under an IND or for which the applicant was not identified as the sponsor, did the applicant certify that it or the applicant's predecessor in interest provided substantial support for the study?
(c) Notwithstanding an answer of "yes" to (a) or (b), are there other reasons to believe that the applicant should not be credited with having "conducted or sponsored" the study? (Purchased studies may not be used as the basis for exclusivity. However, if all rights to the drug are purchased (not just studies on the drug), the applicant may be considered to have sponsored or conducted the studies sponsored or conducted by its predecessor in interest.)

YES ☐ NO ☒

If yes, explain:

=================================================================
Name of person completing form:  Nina Mani, PhD, MPH
Title:  Regulatory Project Manager
Date:  December 24, 2014

Name of Office/Division Director signing form:  Jeffrey Murray, MD MPH
Title:  Deputy Division Director

Form OGD-011347; Revised 05/10/2004; formatted 2/15/05; removed hidden data 8/22/12
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
01/29/2015

JEFFREY S MURRAY
01/29/2015
## ACTION PACKAGE CHECKLIST

### APPLICATION INFORMATION

<table>
<thead>
<tr>
<th>NDA #</th>
<th>205395</th>
<th>NDA Supplement #</th>
<th>0</th>
<th>BLA #</th>
<th>NDA Supplement Type</th>
<th>n/a</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>(an action package is not required for SE8 or SE9 supplements)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Proprietary Name</th>
<th>Prezcobix</th>
</tr>
</thead>
<tbody>
<tr>
<td>Established/Proper Name</td>
<td>darunavir and cobicistat</td>
</tr>
<tr>
<td>Dosage Form</td>
<td>Tablets, 800mg/150mg</td>
</tr>
<tr>
<td>RPM</td>
<td>Nina Mani</td>
</tr>
<tr>
<td>Division</td>
<td>Antiviral Products</td>
</tr>
</tbody>
</table>

### For ALL 505(b)(2) applications, two months prior to EVERY action:

- Review the information in the 505(b)(2) Assessment and submit the draft to CDER OND IO for clearance.
- Check Orange Book for newly listed patents and/or exclusivity (including pediatric exclusivity)
  - No changes
  - New patent/exclusivity (notify CDER OND IO)
  - Date of check:

*Note: If pediatric exclusivity has been granted or the pediatric information in the labeling of the listed drug changed, determine whether pediatric information needs to be added to or deleted from the labeling of this drug.*

### Actions

- Proposed action
- User Fee Goal Date is January 31, 2015

### Previous actions (specify type and date for each action taken)

- None

### Application Characteristics

- Received

---

1 The **Application Information** Section is (only) a checklist. The **Contents of Action Package** Section (beginning on page 2) lists the documents to be included in the Action Package.

2 For resubmissions, 505(b)(2) applications must be cleared before the action, but it is not necessary to resubmit the draft 505(b)(2) Assessment to CDER OND IO unless the Assessment has been substantially revised (e.g., new listed drug, patent certification revised).

3 Answer all questions in all sections in relation to the pending application, i.e., if the pending application is an NDA or BLA supplement, then the questions should be answered in relation to that supplement, not in relation to the original NDA or BLA. For example, if the application is a pending BLA supplement, then a new **RMS-BLA Product Information Sheet for TBP** must be completed.
Review priority: ☑ Standard ☐ Priority
Chemical classification (new NDAs only): Type 4
(Confirm chemical classification at time of approval)

☐ Fast Track
☐ Rolling Review
☐ Orphan drug designation
☐ Breakthrough Therapy designation

☐ Rx-to-OTC full switch
☐ Rx-to-OTC partial switch
☐ Direct-to-OTC

NDAs: Subpart H
☐ Accelerated approval (21 CFR 314.510)
☐ Restricted distribution (21 CFR 314.520)
Subpart I
☐ Approval based on animal studies

☐ Submitted in response to a PMR
☐ Submitted in response to a PMC
☐ Submitted in response to a Pediatric Written Request

BLAs: Subpart E
☐ Accelerated approval (21 CFR 601.41)
☐ Restricted distribution (21 CFR 601.42)
Subpart H
☐ Approval based on animal studies

REMS:
☐ MedGuide
☐ Communication Plan
☐ ETASU
☐ MedGuide w/o REMS
☒ REMS not required

Comments:

- BLAs only: Is the product subject to official FDA lot release per 21 CFR 610.2
  (approvals only)
  ☐ Yes ☐ No

- Public communications (approvals only)
  - Office of Executive Programs (OEP) liaison has been notified of action
    ☐ Yes ☐ No
  - Indicate what types (if any) of information were issued
    ☐ None ☐ FDA Press Release
    ☐ FDA Talk Paper ☐ CDER Q&As
    ☒ Other HIV List serve

- Exclusivity
  - Is approval of this application blocked by any type of exclusivity (orphan, 5-year NCE, 3-year, pediatric exclusivity)?
    ☒ No ☐ Yes
  - If so, specify the type

- Patent Information (NDAs only)
  - Patent Information:
    Verify that form FDA-3542a was submitted for patents that claim the drug for which approval is sought.
    ☒ Verified ☐ Not applicable because drug is an old antibiotic.

CONTENTS OF ACTION PACKAGE

Officer/Employee List

- List of officers/employees who participated in the decision to approve this application and consented to be identified on this list (approvals only)
  ☒ Included

- Documentation of consent/non-consent by officers/employees
  ☒ Included

Version: 1/5/2015
# Action Letters

- Copies of all action letters *(including approval letter with final labeling)*
  - Action(s) and date(s): AP and 1/29/2015

## Labeling

- **Package Insert** *(write submission/communication date at upper right of first page of PI)*
  - Most recent draft labeling *(if it is division-proposed labeling, it should be in track-changes format)*
    - Included
  - Original applicant-proposed labeling
    - Included

- **Medication Guide/Patient Package Insert/Instructions for Use/Device Labeling** *(write submission/communication date at upper right of first page of each piece)*
  - Most-recent draft labeling *(if it is division-proposed labeling, it should be in track-changes format)*
    - Included
  - Original applicant-proposed labeling
    - Included

- **Labels** *(full color* carton and immediate-container labels)* *(write submission/communication date on upper right of first page of each submission)*
  - Most-recent draft labeling
    - Included

- **Proprietary Name**
  - Acceptability/non-acceptability letter(s) *(indicate date(s))*:
    - 5/27/2014
  - Review(s) *(indicate date(s))*:
    - 5/20/2014

- **Labeling reviews** *(indicate dates of reviews)*
  - RPM: 1/28/2015
  - DMPP/PLT (DRISK):
    - 1/5/2015
  - OPDP: 1/5/2015
  - SEALD: None
  - CSS: None
  - Other: None

## Administrative / Regulatory Documents

- **RPM Filing Review**/*Memo of Filing Meeting** *(indicate date of each review)*
  - 5/30/2014

- **All NDA 505(b)(2) Actions**: Date each action cleared by 505(b)(2) Clearance Committee
  - Not a (b)(2)

- **NDAs only**: Exclusivity Summary *(signed by Division Director)*
  - Included

- **Application Integrity Policy (AIP) Status and Related Documents**
  - http://www.fda.gov/ICECI/EnforcementActions/ApplicationIntegrityPolicy/default.htm
  - Applicant is on the AIP
    - Yes
    - No

---

4 Filing reviews for scientific disciplines are NOT required to be included in the action package.
- This application is on the AIP
  - If yes, Center Director's Exception for Review memo *(indicate date)*
  - If yes, OC clearance for approval *(indicate date of clearance communication)*

- Pediatrics *(approvals only)*
  - Date reviewed by PeRC *December 3, 2014*
  - If PeRC review not necessary, explain: 

- Outgoing communications: letters, emails, and faxes considered important to include in the action package by the reviewing office/division (e.g., clinical SPA letters, RTF letter, etc.) *(do not include previous action letters, as these are located elsewhere in package)*

- Internal documents: memoranda, telecons, emails, and other documents considered important to include in the action package by the reviewing office/division (e.g., Regulatory Briefing minutes, Medical Policy Council meeting minutes)

- Minutes of Meetings
  - If not the first review cycle, any end-of-review meeting *(indicate date of mtg)*
  - Pre-NDA/BLA meeting *(indicate date of mtg)*
  - EOP2 meeting *(indicate date of mtg)*
  - Mid-cycle Communication *(indicate date of mtg)*
  - Late-cycle Meeting *(indicate date of mtg)*
  - Other milestone meetings (e.g., EOP2a, CMC pilots) *(indicate dates of mtgs)*

- Advisory Committee Meeting(s)
  - Date(s) of Meeting(s)

Decisional and Summary Memos

- Office Director Decisional Memo *(indicate date for each review)*
  - None

- Division Director Summary Review *(indicate date for each review)*
  - None

- Cross-Discipline Team Leader Review *(indicate date for each review)*
  - None 1/2/2015

- PMR/PMC Development Templates *(indicate total number)*
  - None  Three (3)

Clinical

- Clinical Reviews
  - Clinical Team Leader Review(s) *(indicate date for each review)*
    - No separate review
  - Clinical review(s) *(indicate date for each review)*
    - 12/22/2014
  - Social scientist review(s) (if OTC drug) *(indicate date for each review)*
    - None

- Financial Disclosure reviews(s) or location/date if addressed in another review
  - In Clinical Review/ 12/19/2014 and 12/22/2014

- Clinical reviews from immunology and other clinical areas/divisions/Centers *(indicate date of each review)*
  - None 12/15/2014

- Controlled Substance Staff review(s) and Scheduling Recommendation *(indicate date of each review)*
  - N/A
<table>
<thead>
<tr>
<th>Section</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk Management</td>
<td>None</td>
</tr>
<tr>
<td>- REMS Documents and REMS Supporting Document</td>
<td></td>
</tr>
<tr>
<td>(indicate date(s) of submission(s))</td>
<td></td>
</tr>
<tr>
<td>- REMS Memo(s) and letter(s) (indicate date(s))</td>
<td></td>
</tr>
<tr>
<td>- Risk management review(s) and recommendations (including those by OSE and CSS) (indicate date of each review and indicate location/date if incorporated into another review)</td>
<td>None</td>
</tr>
<tr>
<td>OSI Clinical Inspection Review Summary(ies) (include copies of OSI letters to investigators)</td>
<td>None requested</td>
</tr>
<tr>
<td>Clinical Microbiology</td>
<td>None</td>
</tr>
<tr>
<td>- Clinical Microbiology Team Leader Review(s) (indicate date for each review)</td>
<td>No separate review</td>
</tr>
<tr>
<td>- Clinical Microbiology Review(s) (indicate date for each review)</td>
<td>None 12/22/2014</td>
</tr>
<tr>
<td>Biostatistics</td>
<td>None</td>
</tr>
<tr>
<td>- Statistical Division Director Review(s) (indicate date for each review)</td>
<td>No separate review</td>
</tr>
<tr>
<td>- Statistical Team Leader Review(s) (indicate date for each review)</td>
<td>No separate review</td>
</tr>
<tr>
<td>- Statistical Review(s) (indicate date for each review)</td>
<td>None</td>
</tr>
<tr>
<td>Clinical Pharmacology</td>
<td>None</td>
</tr>
<tr>
<td>- Clinical Pharmacology Division Director Review(s) (indicate date for each review)</td>
<td>No separate review</td>
</tr>
<tr>
<td>- Clinical Pharmacology Team Leader Review(s) (indicate date for each review)</td>
<td>No separate review</td>
</tr>
<tr>
<td>- Clinical Pharmacology review(s) (indicate date for each review)</td>
<td>None 12/23/2014</td>
</tr>
<tr>
<td>OSI Clinical Pharmacology Inspection Review Summary (include copies of OSI letters)</td>
<td>None requested 12/5/2014</td>
</tr>
<tr>
<td>Nonclinical</td>
<td>None</td>
</tr>
<tr>
<td>- Pharmacology/Toxicology Discipline Reviews</td>
<td></td>
</tr>
<tr>
<td>- ADP/T Review(s) (indicate date for each review)</td>
<td>No separate review</td>
</tr>
<tr>
<td>- Supervisory Review(s) (indicate date for each review)</td>
<td>No separate review</td>
</tr>
<tr>
<td>- Pharm/tox review(s), including referenced IND reviews (indicate date for each review)</td>
<td>None 12/24/2014</td>
</tr>
<tr>
<td>- Review(s) by other disciplines/divisions/Centers requested by P/T reviewer (indicate date for each review)</td>
<td>None</td>
</tr>
<tr>
<td>- Statistical review(s) of carcinogenicity studies (indicate date for each review)</td>
<td>No carc</td>
</tr>
<tr>
<td>- ECAC/CAC report/memo of meeting</td>
<td>None</td>
</tr>
<tr>
<td>Included in P/T review, page</td>
<td></td>
</tr>
<tr>
<td>- OSI Nonclinical Inspection Review Summary (include copies of OSI letters)</td>
<td>None requested</td>
</tr>
<tr>
<td>Product Quality</td>
<td>None</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>❯ Product Quality Discipline Reviews</td>
<td></td>
</tr>
<tr>
<td>• ONDQA/OBP Division Director Review(s) <em>(indicate date for each review)</em></td>
<td>No separate review</td>
</tr>
<tr>
<td>• Branch Chief/Team Leader Review(s) <em>(indicate date for each review)</em></td>
<td>No separate review</td>
</tr>
<tr>
<td>• Product quality review(s) including ONDQA biopharmaceutics reviews <em>(indicate date for each review)</em></td>
<td>None Chemistry: 12/16/2014 Biopharmaceutics: 12/5/2014</td>
</tr>
<tr>
<td>❯ Microbiology Reviews</td>
<td></td>
</tr>
<tr>
<td>□ NDAs: Microbiology reviews *(sterility &amp; pyrogenicity) (OPS/NDMS) <em>(indicate date of each review)</em></td>
<td>Not needed</td>
</tr>
<tr>
<td>□ BLAs: Sterility assurance, microbiology, facilities reviews *(OMPO/MAPCB/BMT) <em>(indicate date of each review)</em></td>
<td>Assessment of Microbial Limits: 7/16/2014</td>
</tr>
<tr>
<td>❯ Reviews by other disciplines/divisions/Centers requested by CMC/quality reviewer <em>(indicate date of each review)</em></td>
<td>None</td>
</tr>
<tr>
<td>❯ Environmental Assessment (check one) (original and supplemental applications)</td>
<td></td>
</tr>
<tr>
<td>□ Categorical Exclusion <em>(indicate review date) (all original applications and all efficacy supplements that could increase the patient population)</em></td>
<td></td>
</tr>
<tr>
<td>□ Review &amp; FONSI <em>(indicate date of review)</em></td>
<td>12/17/2014</td>
</tr>
<tr>
<td>□ Review &amp; FONSI <em>(indicate date of each review)</em></td>
<td></td>
</tr>
<tr>
<td>❯ Facilities Review/Inspection</td>
<td></td>
</tr>
<tr>
<td>□ NDAs: Facilities inspections *(include EER printout or EER Summary Report only; do NOT include EER Detailed Report; date completed must be within 2 years of action date) <em>(only original NDAs and supplements that include a new facility or a change that affects the manufacturing sites)</em></td>
<td>Date completed: 9/4/2014 Acceptable (In Chemistry Review)</td>
</tr>
<tr>
<td>□ BLAs: TB-EER *(date of most recent TB-EER must be within 30 days of action date) <em>(original and supplemental BLAs)</em></td>
<td>Date completed: Not applicable</td>
</tr>
<tr>
<td>□ NDAs: Methods Validation <em>(check box only, do not include documents)</em></td>
<td>Completed Requested Not yet requested Not needed (per review)</td>
</tr>
</tbody>
</table>

5 i.e., a new facility or a change in the facility, or a change in the manufacturing process in a way that impacts the Quality Management Systems of the facility.
## Day of Approval Activities

<table>
<thead>
<tr>
<th>Activity</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>For all 505(b)(2) applications:</td>
<td>No changes</td>
</tr>
<tr>
<td>- Check Orange Book for newly listed patents and/or exclusivity (including pediatric exclusivity)</td>
<td></td>
</tr>
<tr>
<td>Finalize 505(b)(2) assessment</td>
<td>Done</td>
</tr>
<tr>
<td>For Breakthrough Therapy(BT) Designated drugs:</td>
<td>Done</td>
</tr>
<tr>
<td>- Notify the CDER BT Program Manager</td>
<td></td>
</tr>
<tr>
<td>Send a courtesy copy of approval letter and all attachments to applicant by fax or secure email</td>
<td>Done</td>
</tr>
<tr>
<td>If an FDA communication will issue, notify Press Office of approval action after confirming that applicant received courtesy copy of approval letter</td>
<td>Done</td>
</tr>
<tr>
<td>Ensure that proprietary name, if any, and established name are listed in the Application Product Names section of DARRTS, and that the proprietary name is identified as the “preferred” name</td>
<td>Done</td>
</tr>
<tr>
<td>Ensure Pediatric Record is accurate</td>
<td>Done</td>
</tr>
<tr>
<td>Send approval email within one business day to CDER-APPROVALS</td>
<td>Done</td>
</tr>
</tbody>
</table>
Hi Karen.

In Table 2 of the USPI, the sedative/hypnotics medications that are listed should not be spaced out (buspirone, diazepam, etc, parenterally administered midazolam and zolpidem). Please follow the spacing in the Word version since it appears that conversion to PDF messes up the spacing.

Thanks,
Nina

Hi Nina,

Janssen acknowledges receipt of the appended NDA 205395 labeling comments from the Division.

Kind regards,

Karen
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
01/27/2015
Hi Karen:

Kindly acknowledge receipt of the attached PDF and Word versions of the labeling for your comments. Please accept the changes you concur with, and only leave in changes/comments that are under negotiation. Please submit your response before **COB, Wednesday, January 28, 2015**.

Regards,
Nina

Nina Mani, Ph.D., MPH
Regulatory Project Manager
FDA/CDER/OND/OAP
Division of Antiviral Products
10903 New Hampshire Avenue, Building 22
Room 6317
Silver Spring, MD 20993-0002
Phone: 240-402-0333
Fax: 301-796-9883
e-mail: Nina.Mani@fda.hhs.gov

**NOTICE:**
Secure email between CDER and sponsors is useful for informal communications when confidential information may be included in the message (for example, trade secrets or patient information). If you have not already established secure email with the FDA and would like to set it up, send an email request to SecureEmail@fda.hhs.gov. Please note that secure email may not be used for formal regulatory submissions to applications (except for 7-day safety reports for INDs not in eCTD format).

34 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
01/27/2015
Hi Karen:

We have the following additional edit in the Full Prescribing Information, Section 16 “How Supplied/Storage and Handling”:

PREZCOBIX (darunavir and cobicistat) tablets, 800mg/150 mg, are supplied as pink, oval-shaped, film-coated tablets debossed with “800” on one side and “TG” on the other side.

If you concur with this presentation please add it in the next iteration of the labeling that you submit.

Kindly acknowledge receipt of this communication.

Regards,

Nina

Good morning Nina,

Janssen acknowledges receipt of the additional NDA 205395 labeling comments.

Kind regards,

Karen
Subject: NDA 205395: Labeling

Hi Karen:

Kindly acknowledge receipt of the attached labeling (Word and PDF) with our comments. When providing your response, please accept all edits we have agreement on. Only leave in edits/changes that are still being negotiated. Please provide your response by Monday, January 26, 2015.

Regards,
Nina

Nina Mani, Ph.D., MPH
Regulatory Project Manager
FDA/CDER/OND/OAP
Division of Antiviral Products
10903 New Hampshire Avenue, Building 22
Room 6317
Silver Spring, MD 20993-0002
Phone: 240-402-0333
Fax: 301-796-9883
e-mail: Nina.Mani@fda.hhs.gov

NOTICE:
Secure email between CDER and sponsors is useful for informal communications when confidential information may be included in the message (for example, trade secrets or patient information). If you have not already established secure email with the FDA and would like to set it up, send an email request to SecureEmail@fda.hhs.gov. Please note that secure email may not be used for formal regulatory submissions to applications (except for 7-day safety reports for INDs not in eCTD format).
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
01/23/2015
Hi Nina,

Janssen acknowledges receipt of this latest set of comments on the labeling and container label for NDA 205395.

Kind regards,

Karen

---

Hi Karen:

Kindly acknowledge receipt of our latest comments on the **labeling and container label**, which is based on the naming conventions we used:

- darunavir and cobicistat (for the FDC)
- darunavir coadministered with cobicistat (or ritonavir) for use of the single entities.

I am attaching both PDF and Word versions of the labeling.

In the **container label** please change:

- [ ] to “darunavir and cobicistat”

Please provide us with the requested changes by Wednesday, January 21, 2015.

Thanks,

Nina

Nina Mani, Ph.D., MPH
Regulatory Project Manager
FDA/CDER/OND/OAP
Division of Antiviral Products
10903 New Hampshire Avenue, Building 22
Room 6317
Silver Spring, MD 20993-0002

Reference ID: 3688765
NOTICE:
Secure email between CDER and sponsors is useful for informal communications when confidential information may be included in the message (for example, trade secrets or patient information). If you have not already established secure email with the FDA and would like to set it up, send an email request to SecureEmail@fda.hhs.gov. Please note that secure email may not be used for formal regulatory submissions to applications (except for 7-day safety reports for INDs not in eCTD format).
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
01/16/2015
Hi Karen:

Please submit ASAP the revised set of specifications that include all of the changes made to-date.

Thanks,
Nina

Good morning Nina,

Janssen is seeking the Division’s advice in managing a CMC documentation oversight that has just been recognized by our CMC colleagues.

As background, during the course of review several changes to drug product specifications updates were provided to the Division and included in our responses to comments from the Agency. Below is a list of the submissions that included specification changes and the reasons for the changes:

- SN0009: Inclusion of microbiological purity acceptance criteria
- SN0014: Tightening of cobicistat degradation acceptance criteria
- SN0017: Tightening of the darunavir dissolution acceptance criterion

Our CMC group confirmed, during a recent review of documentation, that the specifications submitted with SN0017 did include the tighter cobicistat degradation criteria, along with the tighter darunavir dissolution criterion. Unfortunately, this latest set of specifications (SN0017) did not include the addition of the microbiological purity acceptance criteria submitted with SN0009. Therefore, Janssen would like to reconcile the different changes made to the specifications during review, and provide the Division with a revised set of specifications that include all of the changes made to-date as noted in each of the submissions bulleted above.

Is the Division able to accept an updated set of specifications at this time, or offer any guidance to Janssen as how best to approach the reconciliation of the various revisions made to the specifications to-date?

Should you wish to discuss further via telephone, please let me know.

Kind regards,
Karen

Karen Gerry, BSc
North American Regulatory Liaison
Janssen Research & Development LLC
Infectious Diseases

Tel: 416-382-4819
Fax: 416-449-7092
e-mail: kgerry@its.jnj.com

Confidentiality Notice: This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this email is strictly prohibited. If you have received this e-mail in error, please reply to the sender, so that Johnson & Johnson can arrange for proper delivery, and then please delete the message from your inbox. Thank you.

Please consider the environment before printing this email

Reference ID: 3687037
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
01/14/2015
Hi Karen:

Our team has the following revised version of PMR# 3 (12-18 years) that they’d like your concurrence on. The milestone timelines remain unchanged.

**Previous version:**

3. Evaluate the pharmacokinetics, safety, and antiviral activity (efficacy) of darunavir/cobicistat fixed-dose combination (FDC) tablets in HIV-infected pediatric subjects 12 years to less than 18 years of age. The safety and antiviral activity (efficacy) of darunavir/cobicistat FDC tablets in pediatric subjects should be evaluated for a minimum of 24 weeks. A clinical trial in children 12 years to less than 18 years of age may not be required if the dosing recommendation for the FDC tablets can be supported by pediatric trials already conducted with the individual drug products and if the FDC produces similar exposures as the individual components.

**Revision:**

3. Evaluate the pharmacokinetics, safety, and antiviral activity (efficacy) of darunavir/cobicistat fixed-dose combination (FDC) tablets in HIV-infected pediatric subjects 12 years to less than 18 years of age. The safety and antiviral activity (efficacy) of darunavir/cobicistat FDC tablets in pediatric subjects should be evaluated for a minimum of 24 weeks. A clinical trial in children 12 years to less than 18 years of age may not be required if the dosing recommendation for the FDC tablets can be supported by pediatric trials already conducted with the individual drug products and if the FDC produces similar exposures as the individual components.

- Final Protocol Submission: 03/31/2020
- Study/Trial Completion: 12/31/2020
- Final Report Submission: 12/31/2021

Kindly acknowledge receipt of this communication and submit your response by **Wednesday, January 7, 2015**.

Happy New Year!

Regards,
Nina
NOTICE:
Secure email between CDER and sponsors is useful for informal communications when confidential information may be included in the message (for example, trade secrets or patient information). If you have not already established secure email with the FDA and would like to set it up, send an email request to SecureEmail@fda.hhs.gov. Please note that secure email may not be used for formal regulatory submissions to applications (except for 7-day safety reports for INDs not in eCTD format).
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
01/05/2015
MEMORANDUM OF TELECONFERENCE

Teleconference Date: May 28, 2014

Application Number: 205395
Product Name: Darunavir (DRV) and Cobicistat (COBI) Fixed Dose Combination (FDC)
Sponsor/Applicant Name: Janssen Products, LP

Subject: User Fees

FDA Participants
Linda Onaga, Regulatory Project Manager
Nina Mani, Regulatory Project Manager
Karen Winestock, Chief, Project Management Staff

Sponsor/Applicant Participants
Karen Gerry, Manager, Global Regulatory Affairs

1.0 BACKGROUND:

In the December 2012 pre-NDA meeting background package for the DRV and COBI FDC, the sponsor stated that they were not seeking to establish efficacy or safety for the DRV and COBI FDC. Instead, safety and efficacy for DRV and COBI would be established under their individual NDAs. Therefore, the Applicant considers that there will not be any clinical data in the FDC NDA and thus a reduced user fee would be required. The Division was unable to provide a definitive response and requested the sponsor submit a summary of the clinical study and the redlined version of the labeling to the User Fee Staff.

On April 16, 2013, Janssen submitted the requested information to the PIND along with a request for feedback regarding their plan to submit a reduced user fee. The Division sent Janssen a communication that stated that the BE study, TMC114FD1003 would be the pivotal study needed for approval of the DRV and COBI FDC, and based on the information provided it was determined that a reduced user fee would be assessed.

Janssen submitted the NDA in April 2014. Within the application Janssen requested 3 years of exclusivity which, they claimed, was supported by new clinical investigations that are essential for approval. The new clinical investigations included study GS –US-216-0130, a Phase 3b study evaluating DRV and COBI.

The objectives of this teleconference are to obtain clarity on the clinical trial(s) they are referring to which support their exclusivity request, and to inform them of their options with regard to evaluation of clinical data for labeling and its implications.

2.0 DISCUSSION:

Reference ID: 3678507
Janssen interpreted the exclusivity claim to be for the DRV and COBI FDC formulation. The Division informed Janssen that only safety and efficacy evaluations from new clinical trials which are essential to approval can be used to potentially support an exclusivity claim. Therefore, the BE study, which was originally considered pivotal, did not meet the requirements set for exclusivity. However, if Janssen wants the results of Study GS-US-216-0130 in the labeling and use it to support their exclusivity claim, they are subject to the full user fee. If they decide that only the BE study, TMC114IFD1003 is essential for approval and they did not want information from Study GS-US-216-0130 in the labeling, then the user fees they have already paid would be adequate. Janssen was told that they have 5 calendar days to respond. If they decide to include study 0130 results in the labeling, the Agency expects the remaining balance of the full user fee to be submitted with their response.

If the user fee is not received within the allotted time period, Janssen was informed that an “unacceptable for filing” letter will be issued for the application and the review clock would stop.

3.0 ACTION ITEMS:

Janssen will provide the Agency with their decision within 5 calendar days of the phone call as to whether they would like the results from study 0130 in the label.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
12/24/2014
Hi Karen:

We have the following recommendation for the Container Label:

1. Remove (b)(4) to align with DAVP’s recommendation

Please submit the revised container label to the NDA by December 23, 2014. Kindly acknowledge receipt of this communication.

Regards,

Nina

---

Hi Nina,

Janssen acknowledges receipt of the NDA 205395 FDA labeling requests of 11 December 2014.

Could FDA advise if there will be any further questions with respect to the component bottle label, as the Janssen production group would like to initiate printing of the label without having to do so by a ‘risk print’?

Kind regards,

Karen

---

**NOTICE:**

Secure email between CDER and sponsors is useful for informal communications when confidential information may be included in the message (for example, trade secrets or patient information). If you have not already established secure email with the FDA and would like to set it up, send an email request to SecureEmail@fda.hhs.gov. Please note that secure email may not be used for formal regulatory submissions to applications (except for 7-day safety reports for INDs not in eCTD format).
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
12/19/2014
Hi Karen:

We have a follow up request regarding your Clin Pharm submission of today, December 16, 2014:

For amendment 1 to the PBRL-RD-1371/TIE643EL-116433-H/BA10243 method validation report, was the darunavir long term stability data at -20C and -70C for 295 and 588 days generated using freshly prepared calibration standards?

Please provide your response to the NDA by COB, Thursday, December 18, 2014.

Kindly acknowledge receipt of this communication.

Regards,

Nina

Nina Mani
Regulatory Project Manager
FDA/CDER/OAP/DAVP
Bldg 22, Room 6317
240-402-0333

Hi Nina,

Please find this email as notification that Janssen has submitted today (Seq 0021) to NDA 205395 the response to the Division’s Clinical Pharmacology Information Request of 12 December 2014.

Should you have any questions in regards to the submission, please do not hesitate to contact me.

Kind regards,

Karen

Karen Gerry, BSc
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
12/16/2014
Hi Karen:

For the darunavir method validation report, please provide the updated darunavir long term stability data in K2EDTA plasma (and the relevant darunavir certificates of analysis) to support the reported darunavir concentration data from the GS-US-216-130 trial. In the method validation report that was submitted, only 155 days of darunavir long term stability data in K2EDTA plasma was provided.

Please provide this information by December 16, 2014.

Kindly acknowledge receipt of this communication.

Regards,
Nina

Nina Mani, Ph.D., MPH
Regulatory Project Manager
FDA/CDER/OND/OAP
Division of Antiviral Products
10903 New Hampshire Avenue, Building 22
Room 6317
Silver Spring, MD 20993-0002
Phone: 240-402-0333
Fax: 301-796-9883
e-mail: Nina.Mani@fda.hhs.gov

NOTICE:

Secure email between CDER and sponsors is useful for informal communications when confidential information may be included in the message (for example, trade secrets or patient information). If you have not already established secure email with the FDA and would like to set it up, send an email request to SecureEmail@fda.hhs.gov. Please note that secure email may not be used for formal regulatory submissions to applications (except for 7-day safety reports for INDs not in eCTD format).
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
12/12/2014
Hi Minerva,

There was no form FDA-483 issued at [0] or the Belgium clinical facilities, and no significant finding. Both facilities will be classified as NAI. The review memo is pending. Thanks!

Xikui
Hi Karen:

Based on the deferrals in the Agreed Upon PSP the Agency will be proposing the following three PMRs with associated timelines.

In particular, for **#3 (12 years to less than 18 years)**, the Division would like you to propose new dates since we believe that no new formulation development will be needed for this age group. If you want to stay with the dates currently proposed for this age cohort, please provide your justification.

1. Evaluate the pharmacokinetics, safety, and antiviral activity (efficacy) of darunavir/cobicistat fixed dose combination (FDC) age-appropriate formulation in HIV-infected pediatric subjects 3 years to less than 6 years of age and weighing at least 15 kg. The safety and antiviral activity (efficacy) of darunavir/cobicistat FDC tablets in pediatric subjects should be evaluated for a minimum of 24 weeks. A clinical trial in children ages 3 to less than 6 years may not be required if the dosing recommendation for the FDC age-appropriate formulation can be supported by pediatric trials already conducted with the individual drug products and if the age appropriate FDC produces similar exposures as the individual components.
   
   **Protocol submission:** March 31, 2020  
   **Study completion:** December 31, 2020  
   **Study submission:** December 31, 2021

2. Evaluate the pharmacokinetics, safety, and antiviral activity (efficacy) of darunavir/cobicistat fixed dose combination (FDC) age-appropriate formulation in HIV-infected pediatric subjects 6 years to less than 12 years of age. The safety and antiviral activity (efficacy) of darunavir/cobicistat FDC tablets in pediatric subjects should be evaluated for a minimum of 24 weeks. A clinical trial in children ages 6 to less than 12 years may not be required if the dosing recommendation for the FDC age-appropriate formulation can be supported by pediatric trials already conducted with the individual drug products and if the age appropriate FDC produces similar exposures as the individual components.
   
   **Protocol submission:** March 31, 2020  
   **Study completion:** December 31, 2020  
   **Study submission:** December 31, 2021

3. Evaluate the pharmacokinetics, safety, and antiviral activity (efficacy) of darunavir/cobicistat fixed-dose combination (FDC) tablets in HIV-infected pediatric subjects 12 years to less than 18 years of age **[redacted]**. The safety and antiviral activity (efficacy) of darunavir/cobicistat FDC tablets in pediatric subjects should be evaluated for a minimum of 24 weeks. A clinical trial in children 12 years to less than 18
years of age may not be required if the dosing recommendation for the FDC tablets can be supported by pediatric trials already conducted with the individual drug products.

**Protocol submission:** March 31, 2020  
**Study completion:** December 31, 2020  
**Study submission:** December 31, 2021

Kindly acknowledge receipt of this communication and provide your response by **Tuesday, November 25, 2014**. Please also submit your response to the NDA.

Regards,
Nina

---

**From:** Gerry, Karen [JRDA] [mailto:kgerry@its.jnj.com]  
**Sent:** Wednesday, October 15, 2014 2:02 PM  
**To:** Mani, Nina  
**Cc:** Winestock, Karen  
**Subject:** NDA 205395 -- FDA Request of 8 October 2014 (PREA PMC)  
**Importance:** High

Hi Nina,

As requested, Janssen is providing the appended document in regards to the requested timeline information regarding the darunavir/cobicistat formulation for pediatric patients > 3 years to < 18 years of age weighing ≥ 15 kg. Should the Division have any questions in regards to the provided information, please do not hesitate to contact me.

Could you please confirm receipt of this email.

Regards,

Karen

*Karen Gerry, BSc  
North American Regulatory Liaison  
Janssen Research & Development LLC  
Infectious Diseases*
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
11/21/2014
Hi Karen:

Kindly acknowledge receipt of the attached Full Prescriber Information and Patient Information with Division comments (word and PDF) as well as, comments on the container label. Please note that initial edits to the proposed labeling are complete. The Division expects to make additional edits after receiving your response.

In addition we have the following general recommendation, and comments on the container label to ensure safe use of the product.

**A. General Recommendation**

*Replace “TRADENAME” with the conditionally acceptable proprietary name, Prezcobix, where applicable throughout the labels and labeling.*

**B. Container Label**

1. *For consistency between all labels and labeling, add the statement* to the principal display panel (PDP).

2. *Remove* (b) (4)

3. *Move the “Alert: Find out about medicines...” statement to the principal display panel in order to more clearly display this important information. In order to accommodate this change, consider moving the “Each tablet contains...” statement to the side panel.*

Please provide your response by **Monday, November 17** for carton and container label, and Labeling Text.

Thanks.

Nina Mani, Ph.D., MPH
Regulatory Project Manager
FDA/CDER/OND/OAP
Division of Antiviral Products
10903 New Hampshire Avenue, Building 22
Room 6317
Silver Spring, MD 20993-0002

Reference ID: 3655527
NOTICE:
Secure email between CDER and sponsors is useful for informal communications when confidential information may be included in the message (for example, trade secrets or patient information). If you have not already established secure email with the FDA and would like to set it up, send an email request to SecureEmail@fda.hhs.gov. Please note that secure email may not be used for formal regulatory submissions to applications (except for 7-day safety reports for INDs not in eCTD format).
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
11/07/2014
Hi Karen:

We will be setting up a PREA PMR for NDA 205395 for darunavir/cobicistat for pediatric patients. The team requests that you propose dates (mm/dd/yyyy) for protocol submission, study completion, and study submission for each anticipated darunavir/cobicistat formulation for pediatric patients ≥ 3 years to < 18 years of age weighing ≥ 15 kg. Kindly acknowledge receipt of this communication, and please get back to me and Karen Winestock (cced) by October 15, 2014. Please also submit your response to the NDA.

Regards,

Nina

Nina Mani, Ph.D., MPH
Regulatory Project Manager
FDA/CDER/OND/OAP
Division of Antiviral Products
10903 New Hampshire Avenue, Building 22
Room 6317
Silver Spring, MD 20993-0002
Phone: 240-402-0333
Fax: 301-796-9883
e-mail: Nina.Mani@fda.hhs.gov

NOTICE:
Secure email between CDER and sponsors is useful for informal communications when confidential information may be included in the message (for example, trade secrets or patient information). If you have not already established secure email with the FDA and would like to set it up, send an email request to SecureEmail@fda.hhs.gov. Please note that secure email may not be used for formal regulatory submissions to applications (except for 7-day safety reports for INDs not in eCTD format).
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
10/08/2014
INFORMATION REQUEST

Janssen Products, LP
Attention: Karen Gerry, BSc
Manager, Global Regulatory Affairs
1125 Trenton-Harbourton Road
Titusville, NJ 08560

Dear Ms. Gerry:

Please refer to your New Drug Application (NDA) received March 31, 2014 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA), for darunavir/cobicistat tablet, 800 mg/150 mg.

We are reviewing the Chemistry, Manufacturing and Control section of your submission and have the following comments and information requests. We request a prompt written response by September 12, 2014, in order to continue our evaluation of your NDA.

**BioPharmaceutics:**

1. Your proposed dissolution acceptance criterion of \( Q = \frac{\text{%}}{\text{minutes}} \) for darunavir in the FDC tablet is not adequately supported by your data, and is therefore not acceptable. Based on the mean dissolution performance of the clinical and primary stability batches, an acceptance criterion of \( Q = \frac{\text{%}}{\text{minutes}} \) in 30 minutes is recommended for optimal quality control. Further, a final sampling time of 30 minutes is most sensitive to manufacturing variations and dissolution stability changes as summarized in Section 3.2.P.2 of your NDA.

2. Using the clinical batch 2CG7515-X as a reference, provide the results of similarity f1/f2 testing for each evaluated in the manufacturing DOE and development studies to support the proposed PAR for the commercial process. We note that during process development, a final sampling time of 30 minutes is most sensitive to manufacturing variations and dissolution stability changes as summarized in Section 3.2.P.2 of your NDA.

An f2 value of \( \leq \frac{\text{f2}}{\text{value}} \) suggests an inappropriate boundary for a PAR.
**CMC:**

For darunavir drug substance, we have the following recommendations:

1. Add manufacturers’ information for darunavir drug substance in 3.2.S.2.1, as you did for cobicistat drug substance.

2. 

For the drug product, we have the following recommendations:

1. 

2. For acceptance criteria of some of your specified degradants of cobicistat for shelf life/stability studies, we recommend the following revision:

<table>
<thead>
<tr>
<th>Degradant Code</th>
<th>NDA proposed limit (%) at shelf life</th>
<th>FDA proposed limit (%) at shelf life</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b)(4)</td>
<td>(b)(4)</td>
<td>(b)(4)</td>
</tr>
</tbody>
</table>
If you have any questions, call Althea Cuff, Regulatory Health Project Manager, at (301) 796-4061.

Sincerely,

{See appended electronic signature page}

Rapti D. Madurawe, Ph.D.
Branch Chief, Branch V
Division of New Drug Quality Assessment II
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

STEPHEN MILLER
08/27/2014
For R.Madurawe
Hi Nina,

Janssen will review NDA 202022 (SEQ.0004) and the associated ‘Signature page’, and will provide for NDA 205395.

Regards,

Karen

Hi Karen:

Please refer to NDA 202022, rilpivirine and the certification provided on 9/24/2010 Sequence # 0004, 1.9.2 with the “Request for Pediatric Deferral- Signature Page”.
Kindly provide similar certifications for the pediatric deferrals and waivers being sought for the DRV/COBI FDC.

Regards,

Nina

Hi Karen:

Please note that whenever an application triggers PREA and you submit the Agreed iPSP, you are still required to submit waiver and/deferral requests and certification with your NDA submission. Please see the Guidance – “How to comply with the Pediatric Research Equity Act (http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM077855.pdf) for more information. The waiver and deferral requests (including certifications) will be reviewed by the Pediatric Review Committee.

Regards,

Nina

Hi Nina,

Janssen included in the NDA submission (Module 1.9.4) an agreed upon ‘Initial Pediatric Study Plan’ (iPSP) based on the new PSP Guidance of July 2013. Janssen received confirmation of agreement from the Division on 21 March 2013 (appended email correspondence from L. Onaga) whereby the Division stated that...
“...we confirm our agreement to your Agreed iPSP to study darunavir/cobicistat fixed dose combination in pediatric patients 3 to less than 18 years of age with HIV-1 infection. We have completed our review of the submission, and we confirm our agreement to your Agreed iPSP. We have no further comments on your PSP.”, and that the agreed iPSPs should be included in the Janssen New Drug Application.

Janssen was not aware that there was any further documentation needed in the submission in regards to pediatric waivers and deferrals in the study of the darunavir/cobicistat fixed dose combination in pediatric patients 3 to less than 18 years of age with HIV-1 infection.

Could FDA please advise.

Regards,

Karen

Karen Gerry, BSc
North American Regulatory Liaison
Janssen Research & Development LLC
Infectious Diseases

Tel: 416-382-4819
Fax: 416-449-7092
e-mail: kgerry@its.jnj.com

Confidentiality Notice: This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this email is strictly prohibited. If you have received this e-mail in error, please reply to the sender, so that Johnson & Johnson can arrange for proper delivery, and then please delete the message from your inbox. Thank you.

Please consider the environment before printing this email

Hi Karen:

During our review of your submission, we note that you have submitted a request for pediatric waivers and deferral.

However, we could not locate the certification that is required under 21, CFR 314.55. If you have submitted this information, please provide the location.

If not, please submit this information no later than August 4, 2014.

Regards,

Nina

Nina Mani, Ph.D., MPH
Regulatory Project Manager
FDA/CDER/OND/OAP
Division of Antiviral Products
10903 New Hampshire Avenue, Building 22
Room 6317
Silver Spring, MD 20993-0002
Phone: 240-402-0333
Fax: 301-796-9883
e-mail: Nina.Mani@fda.hhs.gov

NOTICE:
Secure email between CDER and sponsors is useful for informal communications when confidential information may be included in the message (for example, trade secrets or patient information). If you have not already established secure email with the FDA and would like to set it up, send an email request to SecureEmail@fda.hhs.gov. Please note that secure email may not be used for formal regulatory submissions to applications (except for 7-day safety reports for INDs not in eCTD format).

Reference ID: 3606492
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
08/07/2014
Hi Karen;

The Clinical team requests the following to aid in the ongoing review of your submission:

In our analysis of Study GS-US-216-0130, we are unable to reproduce the serum glucose abnormalities (hyperglycemia and hypoglycemia) listed in Table 5.5.1. Please provide guidance on how the glucose values in this table were created, including all the variables used.

Kindly acknowledge receipt of this communication and provide your response by Monday, August 18, 2014.

Regards,

Nina

Nina Mani, Ph.D., MPH
Regulatory Project Manager
FDA/CDER/OND/OAP
Division of Antiviral Products
10903 New Hampshire Avenue, Building 22
Room 6317
Silver Spring, MD 20993-0002
Phone: 240-402-0333
Fax: 301-796-9883
e-mail: Nina.Mani@fda.hhs.gov

NOTICE:
Secure email between CDER and sponsors is useful for informal communications when confidential information may be included in the message (for example, trade secrets or patient information). If you have not already established secure email with the FDA and would like to set it up, send an email request to SecureEmail@fda.hhs.gov. Please note that secure email may not be used for formal regulatory submissions to applications (except for 7-day safety reports for INDs not in eCTD format).
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
08/04/2014
The NDA for Darunavir/Cobicistat proposes a waiver of microbial limits testing for drug product release. The applicant provides a suitable rationale for the exclusion of this testing, and microbial limits testing will be performed as a part of the stability program. Therefore, this submission is recommended for approval from the standpoint of product quality microbiology.

The proposed drug product containing Darunavir and Cobicistat is a film-coated tablet for oral administration.

The applicant presents a rationale for waiving microbial enumeration testing for product release.

The applicant provides stability data to demonstrate a lack of microbial growth in the finished product. Microbial enumeration testing was performed for three primary stability batches.
MEMORANDUM

(2CG7514-X, 2CG7515-X, and 2CG7516-X). Product was held at [Redacted], and
[Redacted]. Microbiological specifications for these studies are in agreement with those
described in USP <1111>, and include a total aerobic microbial count of NMT [Redacted].
Microbiological stability data provided met acceptance criteria. Testing was performed using
methods described in USP <61> and USP <62>. A description of method verification studies
was provided in the application. The drug product will be tested for microbial enumeration and
the absence of E. coli annually as part of the stability program.

ADEQUATE

Reviewer Comments – The applicant’s proposal to waive microbial limits testing for product
release is acceptable.

END

Filing Review Information Request

1. You state that microbiological purity of your drug product is ensured by the use of a validated
   manufacturing process, but you do not provide information detailing the validation process or the steps
taken in manufacturing to ensure microbiological quality. Describe these steps and their associated
validation studies.

2. It is unclear if you plan to perform microbial enumeration testing as part of your stability program. Please
   note that you should perform microbial enumeration testing minimally at the initial testing time point.
   Clarify the stability testing schedule for microbial enumeration testing.

3. Provide a statement verifying that microbial enumeration testing methods are suitable for use with the drug
   product.

14 July 2014 Response

The applicant provided the requested information, including a revised stability specification. The information is
reviewed in the preceding section.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIKA A PFEILER
07/16/2014

JOHN W METCALFE
07/16/2014
I concur.
Hi Karen:

Please submit your response by August 11, 2014. Also, if this results in revisions to the label please submit it at the same time.

Thanks,
Nina

---

Hi Nina,

Janssen acknowledges receipt of the below communication. Could you advise as to the timeline for response to FDA?

Regards,
Karen

Karen Gerry, BSc
North American Regulatory Liaison
Janssen Research & Development LLC
Infectious Diseases

Tel: 416-382-4819
Fax: 416-449-7092
e-mail: kgerry@its.jnj.com

Confidentiality Notice: This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this email is strictly prohibited. If you have received this e-mail in error, please reply to the sender, so that Johnson & Johnson can arrange for proper delivery, and then please delete the message from your inbox. Thank you.

Please consider the environment before printing this email
Hi Karen:

In the label submitted as part of the NDA currently under review, the Clinical Virology team has the following comment and request regarding Section 12: Clinical Pharmacology, Sub-section: 12.4 Microbiology, Sub-subsection: Cross-resistance.

In the label it states that ‘…..Darunavir has a less than 10 fold decreased susceptibility in cell culture against 90% of 3309 clinical isolates resistant to amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and/or tipranavir showing that viruses resistant to these PIs remain susceptible to darunavir’. Please identify any of these protease inhibitors for which the percentage of isolates was much less than 90% and provide the supporting data for all. PIs that fall significantly below 90% should be identified in your labels.

Kindly acknowledge receipt of this communication.

Regards,
Nina

Nina Mani, Ph.D., MPH
Regulatory Project Manager
FDA/CDER/OND/OAP
Division of Antiviral Products
10903 New Hampshire Avenue, Building 22
Room 6317
Silver Spring, MD 20993-0002
Phone: 240-402-0333
Fax: 301-796-9883
e-mail: Nina.Mani@fda.hhs.gov

NOTICE:
Secure email between CDER and sponsors is useful for informal communications when confidential information may be included in the message (for example, trade secrets or patient information). If you have not already established secure email with the FDA and would like to set it up, send an email request to SecureEmail@fda.hhs.gov. Please note that secure email may not be used for formal regulatory submissions to applications (except for 7-day safety reports for
INDs not in eCTD format).
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
07/15/2014
Yes, that is fine.

Thanks.

From: Nair, Nancy [JRDUS] [mailto:Nair@its.jnj.com]  
Sent: Wednesday, June 04, 2014 12:31 PM  
To: Mani, Nina  
Subject: RE: NDA 205-123/S-002

HI Nina

Thanks for the guidance. 2 months from the COSMOS Submission (May 6, 2014) would be July 6, 2014. Since it falls on a Sunday, would DAVP agree to us submitting it by the next business day, Monday, July 7?

Thanks

Nancy

From: Mani, Nina [mailto:Nina.Mani@fda.hhs.gov]  
Sent: Wednesday, June 04, 2014 12:07 PM  
To: Nair, Nancy [JRDUS]  
Subject: RE: NDA 205-123/S-002

HI Nancy:

Our clinical team requests that you submit a 2 month safety update, including a summary of the postmarketing safety experience with the combination regimen. Kindly acknowledge receipt of this communication.

Regards,

Nina

From: Nair, Nancy [JRDUS] [mailto:Nair@its.jnj.com]  
Sent: Tuesday, June 03, 2014 12:45 PM  
To: Mani, Nina  
Subject: NDA 205-123/S-002

Hi Nina

In reference to NDA 205-123/S-002, the COSMOS submission, Janssen would like to confirm that we would not be required to submit a 2 or 4 month safety update report for the referenced sNDA. Janssen intends on providing safety information from all the ongoing studies in the upcoming PBRER (reporting period Nov 22-2013- May 21,2014) and the PADER (reporting period May 22-
2014-August 21, 2014). Kindly confirm if this is acceptable with the Division or provide further guidance.

Thanks very much and I look forward to your response,
Nancy

Nancy V. Nair, PharmD, MBA
Associate Director, Global Regulatory Affairs
Janssen Research & Development, LLC
920 Route 202 South
Raritan NJ 08869
Office: (908) 927-3779
Fax: (908) 704-1501
Dear Ms. Gerry:

Please refer to your Investigational New Drug Application (IND) submitted under section 505(i) of the Federal Food, Drug, and Cosmetic Act, and your New Drug Application (NDA) dated and received March 31, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Darunavir/Cobicistat Tablets, 800mg/150 mg.

We also refer to:

- Your correspondence to your IND, dated and received January 14, 2014, requesting review of your proposed proprietary name, Prezcobix
- Your correspondence to your NDA, dated and received March 31, 2014, requesting review of your proposed proprietary name, Prezcobix

We have completed our review of the proposed proprietary name Prezcobix, and have concluded that this name is acceptable.

If any of the proposed product characteristics as stated in your March 31, 2014, submission are altered prior to approval of the marketing application, the proprietary name should be resubmitted for review.

If you have any questions regarding the contents of this letter or any other aspects of the proprietary name review process, contact Danyal Chaudhry, Safety Regulatory Project Manager in the Office of Surveillance and Epidemiology, at (301) 796-3813. For any other information regarding this application, contact the Office of New Drugs (OND) Regulatory Project Manager Nina Mani, at (240) 402-0333.

Sincerely,

{See appended electronic signature page}

Kellie A. Taylor, Pharm.D., MPH
Deputy Director
Office of Medication Error Prevention and Risk Management
Office of Surveillance and Epidemiology
Center for Drug Evaluation and Research

Reference ID: 3513071
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

AZEEM D CHAUDHRY
05/27/2014

TODD D BRIDGES on behalf of KELLIE A TAYLOR
05/27/2014
Hi Karen:

Our review team has the following request for this NDA:

Please submit the contact information (e-mail, telephone and fax numbers) for the clinical and analytical facilities/sites associated with Study TMC 1141FD1003 titled “A single-dose, open-label, 3-panel, randomized, pivotal crossover study to assess the bioequivalence of darunavir when coadministered with cobicistat as either a fixed dose combination tablet (G006) or as single agents under fed and fasted conditions in healthy subjects” to the NDA.

Kindly acknowledge receipt of this communication.

Regards,
Nina

Nina Mani, Ph.D., MPH
Regulatory Project Manager
FDA/CDER/OND/OAP
Division of Antiviral Products
10903 New Hampshire Avenue, Building 22
Room 6317
Silver Spring, MD 20993-0002
Phone: 240-402-0333
Fax: 301-796-9883
e-mail: Nina.Mani@fda.hhs.gov

NOTICE:
Secure email between CDER and sponsors is useful for informal communications when confidential information may be included in the message (for example, trade secrets or patient information). If you have not already established secure email with the FDA and would like to set it up, send an email request to SecureEmail@fda.hhs.gov. Please note that secure email may not be used for formal regulatory submissions to applications (except for 7-day safety reports for INDs not in eCTD format).
NDA 205395

Janssen Products, LP
1125 Trenton-Harbourton Road
Titusville, NJ 08560

ATTENTION: Karen Gerry, B.Sc.
Manager, Global Regulatory Affairs

Dear Ms. Gerry:

Please refer to your New Drug Application (NDA) dated and received March 31, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Darunavir/Cobicistat, Tablets, Darunavir 800 mg/Cobicistat 150 mg.

We also refer to your correspondence dated and received March 31, 2014, requesting a review of your proposed proprietary name, Prezcobix. Upon preliminary review of your submission, we have determined that it is a complete submission as described in our Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names.

Therefore, the user fee goal date is June 29, 2014.

If you have any questions regarding the contents of this letter or any other aspects of the proprietary name review process, contact Danyal Chaudhry, Regulatory Project Manager in the Office of Surveillance and Epidemiology, at (301) 796-3813. For any other information regarding this application, contact Nina Mani, Regulatory Project Manager in the Office of New Drugs, at (240) 402-0333.

Sincerely,

{See appended electronic signature page}

Danyal Chaudhry, M.P.H.
Safety Regulatory Project Manager
Office of Surveillance and Epidemiology
Center for Drug Evaluation and Research

Reference ID: 3483737
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

AZEEM D CHAUDHRY
04/04/2014
NDA 205395

NDA ACKNOWLEDGMENT

Janssen Products, LP
Attention: Karen Gerry, BSc
Manager, Global Regulatory Affairs
1125 Trenton-Harbourton Road
Titusville, NJ 08560

Dear Ms. Gerry:

We have received your New Drug Application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

Name of Drug Product: darunavir/cobicistat, tablet (800 mg/150 mg)

Date of Application: March 31, 2014

Date of Receipt: March 31, 2014

Our Reference Number: NDA 205395

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on May 30, 2014, in accordance with 21 CFR 314.101(a).

If you have not already done so, promptly submit the content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Failure to submit the content of labeling in SPL format may result in a refusal-to-file action under 21 CFR 314.101(d)(3). The content of labeling must conform to the content and format requirements of revised 21 CFR 201.56-57.

You are also responsible for complying with the applicable provisions of sections 402(i) and 402(j) of the Public Health Service Act (PHS Act) [42 USC §§ 282 (i) and (j)], which was amended by Title VIII of the Food and Drug Administration Amendments Act of 2007 (FDAAA) (Public Law No, 110-85, 121 Stat. 904).

The NDA number provided above should be cited at the top of the first page of all submissions to this application. Send all submissions, electronic or paper, including those sent by overnight mail or courier, to the following address:
Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Antiviral Products  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

All regulatory documents submitted in paper should be three-hole punched on the left side of the page and bound. The left margin should be at least three-fourths of an inch to assure text is not obscured in the fastened area. Standard paper size (8-1/2 by 11 inches) should be used; however, it may occasionally be necessary to use individual pages larger than standard paper size. Non-standard, large pages should be folded and mounted to allow the page to be opened for review without disassembling the jacket and refolded without damage when the volume is shelved. Shipping unbound documents may result in the loss of portions of the submission or an unnecessary delay in processing which could have an adverse impact on the review of the submission. For additional information, please see http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/DrugMasterFilesDMFs/ucm073080.htm.

Secure email between CDER and applicants is useful for informal communications when confidential information may be included in the message (for example, trade secrets or patient information). If you have not already established secure email with the FDA and would like to set it up, send an email request to SecureEmail@fda.hhs.gov. Please note that secure email may not be used for formal regulatory submissions to applications.

If you have any questions, call me at (240) 402-0333 or the Division’s number at (301) 796-1500.

Sincerely,

{See appended electronic signature page}

Nina Mani, PhD, MPH  
Regulatory Project Manager  
Division of Antiviral Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NINA MANI
04/03/2014